Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2017BioDrugsOpen Access

Recombinant AAV particles lacking viral genes have proven to be one of the safest strategies for gene therapies.

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Authors

MNMichael NasoBTBrian TomkowiczWPWilliam L. Perry

Discussion

Loading...

Member takes

Overview

Supports cautious AAV use in gene therapy trials; leaves open need for randomized long-term safety data.

Structured PICO

I
Intervention
Adeno-associated virus (AAV) vectors

AAV is highlighted as a safe and promising vector for clinical-stage experimental gene therapies.

Cite This Study

Naso et al. (2017) studied this question.

synapsesocial.com/papers/69d7429658d71cbec648f5b1https://doi.org/10.1007/s40259-017-0234-5
View Full Paper
Ask AI
Bookmark
Share